Agenus(US:AGEN) Prnewswire·2024-10-14 09:45Core Viewpoint - The Gross Law Firm has announced a class action lawsuit against Agenus Inc. for allegedly issuing false and misleading statements regarding the effectiveness of its immuno-oncology products, botensilimab and balstilimab, during the class period from January 23, 2023, to July 17, 2024 [1]. Group 1 - The class action alleges that the combination therapy of botensilimab and balstilimab was less effective than what was communicated to investors [1]. - The complaint states that the clinical results and regulatory and commercial prospects of botensilimab and balstilimab were overstated [1]. - As a result of these misleading statements, the company's public disclosures were deemed materially false and misleading throughout the relevant period [1]. Group 2 - Shareholders who purchased shares of Agenus during the specified class period are encouraged to register for the class action, with a deadline of November 5, 2024, to seek lead plaintiff status [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates on the case's progress [2]. - Participation in the case incurs no cost or obligation for the shareholders [2].